- •Multi-institutional study of high risk variant carriers after risk reducing procedure
- •Receiving hormonal therapy after a risk reductive procedure was not associated with increased risk of malignancy.
- •There were no subsequent gynecologic carcinomas identified in either group.
- •Being younger and undergoing other risk reductive procedures increased use of hormonal therapy.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
- Prophylactic and risk-reducing bilateral Salpingo-oophorectomy: recommendations based on risk of ovarian cancer.Obstet. Gynecol. 2010; 116: 733-743
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.15. 2017: 9 (1)
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.15. 2017: 1465 (12)
- A prospective study of risk-reducing Salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian Cancer: design and baseline characteristics: a gynecologic oncology group study.Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2008; 17: 594-604
- Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.Obstet. Gynecol. 2013; 121: 14-24
- Risks and benefits of estrogen plus progestin in healthy postmenopausal WomenPrincipal results from the Women’s Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.J. Natl. Cancer Inst. 2008; 100: 1361-1367
- Hormone replacement therapy after oophorectomy and breast Cancer risk among BRCA1 mutation carriers.JAMA Oncology. 2018; 4: 1059-1065
- Is hormone replacement therapy safe in women with a BRCA mutation? A systematic review of the contemporary literature.Am. J. Clin. Oncol. 2018; 41: 313-315
- Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.Gynecol. Oncol. 2019; 153: 192-200
- Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers.Hered Cancer Clin Pract. 2015; 13: 10
- Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Crit. Rev. Oncol. Hematol. 2018; 132: 111-115
- Estrogen receptor status in BRCA1 and BRCA2-related breast cancer: the influence of age, grade, and histological type.Clin. Cancer Res. 2004; 10: 2029-2034
- BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.Gynecol. Oncol. 2004; 92: 521-524
- The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.Gynecol. Oncol. 2007; 104: 7-10
- Risk of endometrial carcinoma associated with BRCA mutation.Gynecol. Oncol. 2001; 80: 395-398
- Uterine cancer after risk-reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations uterine cancer after risk-reducing Salpingo-oophorectomy uterine cancer after risk-reducing Salpingo-oophorectomy.JAMA Oncology. 2016; 2: 1434-1440
- Endometrial cancer and lynch syndrome: clinical and pathologic considerations.Cancer Control. 2009; 16: 14-22
- Lynch syndrome presenting as endometrial cancer.Clin. Chem. 2014; 60: 111
- WISP: A Prospective, Multi-Center Trial of Salpingectomy with Delayed Oophorectomy Versus Risk Reducing Salpingo-Oophorectomy in Women at Increased Risk for Hereditary Ovarian Cancer Paper Presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16–19, 2019.2019 (Honolulu, Hawaii)
- Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations.Gynecol. Oncol. 2018; 150: 79-84
. M.P. Steenbeek MGH, D. TUBA group, R.P.M.G. Hermens and J.A. de Hullu. Worry and regret in the prospective multicentre TUBA study in BRCA1/2 mutation carriers. Paper Presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16–19, 2019, 2019; (Honolulu, Hawaii).
☆Grant support: REDCap: Supported by Clinical and Translational Science Award (CTSA) Grant [UL1 TR000448] and Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant P30 CA091842.